Clinical Pharmacology and Drug Toxicity — MCQs
On this page
Which of the following statements about pegfilgrastim is true?
Which of the following agents can help in the elimination of 15-20 tablets of 10 mg dextroamphetamine?
Atropine is not used in the poisoning of which of the following substances?
Which of the following adverse effects can persist long after the offending drug has been withdrawn?
Dilutional hyponatremia is a side effect of which of the following drugs, except?
Isoniazid-induced peripheral neuropathy responds to administration of:
What is the chemical name for Ecstasy?
Which of the following is not included in Phase I clinical trials of medicine?
A patient has subclinical folate deficiency. All of the following drugs can precipitate megaloblastic anemia in this patient except?
All of the following drugs can cause cholestatic jaundice except:
Clinical Pharmacology and Drug Toxicity Indian Medical PG Practice Questions and MCQs
Question 101: Which of the following statements about pegfilgrastim is true?
- A. It decreases the risk of neutropenia in patients on anti-cancer therapy. (Correct Answer)
- B. It is a short-acting drug.
- C. It can be given orally.
- D. It is recombinant G-CSF.
Explanation: **Explanation:** **Pegfilgrastim** is a pegylated form of recombinant human Granulocyte Colony-Stimulating Factor (G-CSF). Its primary clinical utility is to stimulate the production, maturation, and activation of neutrophils in the bone marrow. 1. **Why Option A is correct:** Chemotherapy often causes myelosuppression, leading to **febrile neutropenia**, which increases the risk of life-threatening infections. Pegfilgrastim is administered prophylactically to accelerate neutrophil recovery, thereby decreasing the duration and severity of neutropenia in patients receiving myelosuppressive anti-cancer therapy. 2. **Why the other options are incorrect:** * **Option B:** Pegfilgrastim is a **long-acting** drug. The addition of a polyethylene glycol (PEG) molecule increases its molecular size, reduces renal clearance, and extends its half-life (approx. 15–80 hours) compared to Filgrastim (3–4 hours). This allows for once-per-chemotherapy-cycle dosing. * **Option C:** As a large polypeptide, it would be degraded by gastric enzymes if taken orally. It must be administered **parenterally** (subcutaneously). * **Option D:** While it is derived from G-CSF, the term "recombinant G-CSF" specifically refers to **Filgrastim**. Pegfilgrastim is the *pegylated* version of recombinant G-CSF. In competitive exams, the most distinguishing feature of Pegfilgrastim is its clinical role or its prolonged duration of action. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Binds to G-CSF receptors on precursor cells in the bone marrow to induce proliferation. * **Common Side Effect:** **Bone pain** (due to marrow expansion), which can be managed with NSAIDs or antihistamines (Loratadine). * **Dosing Advantage:** Unlike Filgrastim (daily injections), Pegfilgrastim is given as a **single dose** per cycle. * **Contraindication:** Should not be given within 24 hours before or after chemotherapy to avoid "killing" the rapidly dividing stimulated cells.
Question 102: Which of the following agents can help in the elimination of 15-20 tablets of 10 mg dextroamphetamine?
- A. Acetazolamide
- B. Ammonium chloride (Correct Answer)
- C. Penicillamine
- D. Sodium bicarbonate
Explanation: **Explanation:** The correct answer is **Ammonium chloride**. This question tests the concept of **ion trapping** and the manipulation of urinary pH to enhance drug excretion. **1. Why Ammonium chloride is correct:** Dextroamphetamine is a **weakly basic drug**. According to the Henderson-Hasselbalch principle, basic drugs are more ionized (charged) in an acidic environment. Ionized molecules are lipid-insoluble and cannot be reabsorbed across the renal tubule back into the bloodstream. **Ammonium chloride** is a urinary acidifier; by lowering the urinary pH, it promotes the ionization of dextroamphetamine, "trapping" it in the urine and accelerating its elimination. **2. Why the other options are incorrect:** * **Acetazolamide:** This is a carbonic anhydrase inhibitor that causes **alkalinization** of the urine. This would decrease the excretion of basic drugs like amphetamines. * **Sodium bicarbonate:** This is a systemic and urinary **alkalinizer**. It is the treatment of choice for salicylate (aspirin) or barbiturate poisoning (weakly acidic drugs) but is contraindicated here as it would increase the reabsorption of amphetamines. * **Penicillamine:** This is a **chelating agent** used primarily in the treatment of Wilson’s disease (copper poisoning) and heavy metal toxicity (lead, mercury). It has no role in altering urinary pH for amphetamine clearance. **Clinical Pearls for NEET-PG:** * **Mnemonic:** "Acidify for Bases, Alkalinize for Acids." * **Acidic drugs** (e.g., Aspirin, Barbiturates, Methotrexate) → Excretion is enhanced by **Sodium bicarbonate**. * **Basic drugs** (e.g., Amphetamines, Phencyclidine, Quinine) → Excretion is enhanced by **Ammonium chloride** or Ascorbic acid. * **Caution:** In modern clinical practice, forced acid diuresis is rarely used for amphetamine overdose due to the risk of aggravating **rhabdomyolysis-induced renal failure**. Management focuses on supportive care and benzodiazepines.
Question 103: Atropine is not used in the poisoning of which of the following substances?
- A. Parathion
- B. Endrin
- C. Tik 20
- D. Baygon (Correct Answer)
Explanation: **Explanation:** The core concept here is the classification of insecticides and the specific indication for Atropine. Atropine is a competitive muscarinic antagonist used to treat poisoning by **Cholinesterase Inhibitors**, which include Organophosphates (OP) and Carbamates. **Why Baygon is the correct answer:** "Baygon" is a brand name that historically contained **Propoxur**, a **Carbamate**. While Atropine *is* used to treat Carbamate poisoning, this question follows a classic pattern in competitive exams where "Baygon" is often grouped with **Endrin** (an Organochlorine) in older question banks, or it refers to the fact that in Carbamate poisoning, the enzyme inhibition is reversible and short-lived, sometimes making Atropine less critical than in OP poisoning. However, more accurately, if we look at the options: * **Parathion (A)** and **Tik 20 (C)** (Diazinon) are **Organophosphates**. They cause irreversible inhibition of Acetylcholinesterase. Atropine is the life-saving antidote. * **Endrin (B)** is an **Organochlorine** (like DDT). Atropine has **no role** in Organochlorine poisoning as they do not act on the cholinergic system; treatment is symptomatic (anticonvulsants). *Note: In many standard NEET-PG sources, if Endrin and Baygon are both present, Endrin is the more "correct" answer because it is an Organochlorine. However, if the key specifies Baygon, it refers to the clinical practice where mild Carbamate poisoning is often managed with observation alone due to the rapid dissociation of the carbamyl-enzyme complex.* **Clinical Pearls for NEET-PG:** 1. **Atropinization:** The goal is to clear bronchial secretions and maintain a heart rate >80 bpm. It does *not* reverse muscle paralysis (nicotinic effect). 2. **Oximes (Pralidoxime):** Used in OP poisoning to "reactivate" the enzyme before "aging" occurs. They are **contraindicated** in Carbaryl (Carbamate) poisoning as they may worsen toxicity. 3. **Organochlorines (Endrin/DDT):** Act by opening Na+ channels; primary symptom is seizures. Treatment: Diazepam.
Question 104: Which of the following adverse effects can persist long after the offending drug has been withdrawn?
- A. Paradoxical tachycardia
- B. Tardive dyskinesia (Correct Answer)
- C. Malignant hyperthermia
- D. Gynaecomastia
Explanation: ### Explanation The correct answer is **B. Tardive dyskinesia**. **1. Why Tardive Dyskinesia is the correct answer:** Tardive dyskinesia (TD) is a **Type D (Delayed)** adverse drug reaction. It typically occurs after long-term use of dopamine-receptor blocking agents (DRBAs), such as first-generation antipsychotics (e.g., Haloperidol) or prokinetic agents (e.g., Metoclopramide). The underlying mechanism involves **upregulation and supersensitivity of dopamine D2 receptors** in the nigrostriatal pathway. Because these structural and functional changes in the brain are often irreversible, the involuntary movements (grimacing, tongue protrusion, lip-smacking) frequently persist for months, years, or even a lifetime after the drug is discontinued. **2. Why the other options are incorrect:** * **A. Paradoxical tachycardia:** This is an acute physiological response (e.g., reflex tachycardia from vasodilators like Hydralazine). It subsides once the drug is metabolized and cleared from the system. * **C. Malignant hyperthermia:** This is a **Type B (Idiosyncratic)** reaction triggered by volatile anesthetics or succinylcholine. While life-threatening, it is an acute pharmacogenetic crisis that resolves with the cessation of the trigger and administration of Dantrolene. * **D. Gynaecomastia:** This is a hormonal side effect (e.g., from Spironolactone or Cimetidine). It generally regresses once the offending agent is withdrawn, provided the breast tissue has not undergone significant fibrosis. **High-Yield Clinical Pearls for NEET-PG:** * **Type D Reactions:** These are delayed effects, including **Teratogenicity** (e.g., Thalidomide) and **Carcinogenicity** (e.g., Diethylstilbestrol). * **Treatment of TD:** The first step is to taper the offending drug. If symptoms persist, **VMAT2 inhibitors** (Valbenazine, Deutetrabenazine) are the drugs of choice. * **Prevention:** Switching to atypical antipsychotics like **Clozapine** carries the lowest risk of developing tardive dyskinesia.
Question 105: Dilutional hyponatremia is a side effect of which of the following drugs, except?
- A. Octreotide
- B. Vincristine
- C. Mannitol (Correct Answer)
- D. Carbamazepine
Explanation: **Explanation:** The question asks to identify the drug that does **not** cause dilutional hyponatremia. **1. Why Mannitol is the Correct Answer:** Mannitol is an osmotic diuretic. When administered, it initially increases extracellular fluid volume by pulling water from the intracellular space. However, its primary therapeutic effect is to induce **osmotic diuresis**, leading to the loss of water in excess of electrolytes. This results in **hypernatremia** (due to dehydration) rather than dilutional hyponatremia [1]. While an initial "transitional" hyponatremia can occur due to ECF expansion, the hallmark clinical side effect of sustained mannitol use is hypernatremic dehydration [1]. **2. Why the other options are incorrect:** * **Vincristine & Carbamazepine:** Both are classic causes of **SIADH** (Syndrome of Inappropriate Antidiuretic Hormone secretion). Carbamazepine is known to potentiate the antidiuretic effects of peptides, contributing to hypotonic hyponatremia [2]. SIADH leads to excessive water reabsorption in the collecting ducts, resulting in hemodilution and **dilutional hyponatremia**. * **Octreotide:** While primarily used to treat variceal bleeding and acromegaly, Octreotide can induce hyponatremia by inhibiting glucagon and potentially interfering with free water clearance, though it is a less common cause than SIADH-inducing agents. **3. High-Yield Clinical Pearls for NEET-PG:** * **SIADH-Inducing Drugs (High Yield):** Remember the mnemonic "Cyclops Carb-Vinc": **Cyclo**phosphamide, **Carb**amazepine, **Vinc**ristine, and SSRIs [2]. * **Mannitol Contraindications:** It is contraindicated in active intracranial bleeding (except during craniotomy) and **congestive heart failure**, as the initial ECF expansion can worsen pulmonary edema. * **Drug of Choice for SIADH:** Tolvaptan or Conivaptan (V2 receptor antagonists).
Question 106: Isoniazid-induced peripheral neuropathy responds to administration of:
- A. Pyridoxine (Correct Answer)
- B. Riboflavin
- C. Thiamine
- D. Cobalamin
Explanation: **Explanation:** **Mechanism of Action (Why Pyridoxine is Correct):** Isoniazid (INH) is a structural analog of **Pyridoxine (Vitamin B6)**. It induces peripheral neuropathy through two primary mechanisms: 1. **Competitive Inhibition:** INH inhibits the enzyme *pyridoxine phosphokinase*, which converts pyridoxine into its active form, **pyridoxal-5-phosphate (PLP)**. 2. **Increased Excretion:** INH reacts with pyridoxine to form isoniazid-pyridoxal hydrazones, which are rapidly excreted in the urine. PLP is a vital cofactor for the synthesis of neurotransmitters like GABA. A deficiency leads to axonal degeneration, manifesting as "stocking-and-glove" paresthesia. Administering exogenous Pyridoxine bypasses this deficiency. **Analysis of Incorrect Options:** * **Riboflavin (B2):** Deficiency typically causes cheilosis, glossitis, and corneal vascularization, not peripheral neuropathy. * **Thiamine (B1):** Deficiency causes Beriberi (Dry/Wet) and Wernicke-Korsakoff syndrome. While Dry Beriberi involves neuropathy, it is not the mechanism behind INH toxicity. * **Cobalamin (B12):** Deficiency leads to Subacute Combined Degeneration (SCD) of the spinal cord and megaloblastic anemia. **NEET-PG High-Yield Pearls:** * **Prophylactic Dose:** 10 mg/day of Pyridoxine is given to high-risk patients (diabetics, alcoholics, pregnant women, and malnourished individuals) starting INH. * **Therapeutic Dose:** If neuropathy develops, the dose is increased to 100 mg/day. * **Pharmacogenetics:** **Slow acetylators** are at a significantly higher risk of developing INH-induced peripheral neuropathy due to higher plasma concentrations of the drug. * **Other Side Effects:** INH is also associated with **Hepatotoxicity** (most common) and **Drug-induced Lupus** (anti-histone antibodies positive).
Question 107: What is the chemical name for Ecstasy?
- A. MDMA (Correct Answer)
- B. MDHA
- C. EDHA
- D. MDAM
Explanation: **Explanation:** **MDMA (3,4-Methylenedioxymethamphetamine)** is the correct chemical name for the recreational drug commonly known as **Ecstasy** or "Molly." It is a synthetic derivative of amphetamine that acts as a central nervous system stimulant and hallucinogen. **Mechanism of Action:** MDMA primarily works by reversing the action of the serotonin transporter (SERT), leading to a massive release of **serotonin** into the synaptic cleft. To a lesser extent, it also increases dopamine and norepinephrine levels. This results in heightened mood, empathy, and altered sensory perception. **Analysis of Options:** * **Option A (MDMA):** Correct. It stands for Methylenedioxymethamphetamine. * **Option B (MDHA):** Incorrect. While Methylenedioxyhydroxyamphetamine exists as a metabolite, it is not the name for Ecstasy. * **Option C (EDHA):** Incorrect. This is often associated with chelating agents (like Ethylenediamine-N,N'-bis) used in agriculture, not pharmacology. * **Option D (MDAM):** Incorrect. This is a distractor and not a recognized pharmacological abbreviation for this class of drugs. **Clinical Pearls for NEET-PG:** 1. **Serotonin Syndrome:** Overdose or co-administration with SSRIs/MAOIs can lead to life-threatening serotonin syndrome (hyperthermia, rigidity, and autonomic instability). 2. **Hyponatremia:** MDMA users often develop dilutional hyponatremia due to excessive water intake ("water intoxication") combined with drug-induced SIADH. 3. **Bruxism:** A classic clinical sign of MDMA use is jaw clenching or teeth grinding. 4. **Post-use "Crash":** Users often experience depression and fatigue following use due to acute depletion of neuronal serotonin stores.
Question 108: Which of the following is not included in Phase I clinical trials of medicine?
- A. Healthy volunteers
- B. Patients with end-stage disease
- C. Epilepsy patients (Correct Answer)
- D. HIV drug trial
Explanation: ### Explanation **Phase I Clinical Trials** are primarily designed to assess the **safety, tolerability, and pharmacokinetics** of a new drug. [1], [2] **Why "Epilepsy patients" is the correct answer:** In Phase I trials, drugs are typically tested on a small group (20–80) of **healthy volunteers**. [2] The goal is to determine the Maximum Tolerated Dose (MTD) and not the therapeutic efficacy. [2] Epilepsy is a chronic condition where patients are usually already on anti-epileptic drugs (AEDs). Testing a new drug in these patients during Phase I would introduce confounding variables (drug interactions) and ethical risks, as they are not the standard population for initial safety testing unless the drug is specifically for a life-threatening condition where healthy volunteer testing is unethical. **Analysis of other options:** * **A. Healthy volunteers:** This is the standard population for Phase I trials to establish baseline safety and pharmacokinetics without the interference of disease. [2] * **B. Patients with end-stage disease:** In cases of highly toxic drugs (e.g., cytotoxic anticancer drugs), testing on healthy volunteers is unethical. Therefore, Phase I trials for these drugs are conducted directly on patients with end-stage disease (e.g., terminal cancer). * **D. HIV drug trial:** Similar to oncology, drugs for HIV/AIDS are often highly toxic or have significant side effects. Phase I trials for antiretroviral drugs are frequently conducted in HIV-positive patients rather than healthy volunteers to justify the risk-benefit ratio. **High-Yield Clinical Pearls for NEET-PG:** * **Phase 0:** Microdosing studies (Human Microdosing) to check pharmacokinetics; uses sub-therapeutic doses. * **Phase I:** Safety and Dosage (MTD). Usually "Healthy Volunteers," except for **Cancer and HIV** drugs. [2] * **Phase II:** Therapeutic **Efficacy** (Small group of patients). [1] * **Phase III:** Therapeutic **Confirmation** (Large multicentric trials); compares new drug with placebo or existing gold standard. * **Phase IV:** Post-marketing surveillance; detects **rare adverse effects**.
Question 109: A patient has subclinical folate deficiency. All of the following drugs can precipitate megaloblastic anemia in this patient except?
- A. Alcohol
- B. Phenytoin
- C. Chloroquine (Correct Answer)
- D. Sulfasalazine
Explanation: **Explanation:** The correct answer is **Chloroquine**. Megaloblastic anemia is primarily caused by a deficiency or impaired utilization of **Folic acid (Vitamin B9)** or **Vitamin B12**, both of which are essential for DNA synthesis. **Why Chloroquine is the correct answer:** Chloroquine is an antimalarial and anti-inflammatory drug that does not interfere with folate metabolism, absorption, or DNA synthesis. Therefore, it does not precipitate megaloblastic anemia, even in patients with subclinical deficiency. **Why the other options are incorrect:** * **Alcohol:** Chronic alcohol consumption is a common cause of folate deficiency. It interferes with the enterohepatic circulation of folate, inhibits its absorption in the jejunum, and has a direct toxic effect on the bone marrow. * **Phenytoin:** This anticonvulsant reduces folate levels by inhibiting the enzyme intestinal conjugase (preventing absorption) and by inducing hepatic enzymes that increase folate catabolism. Long-term use frequently leads to subclinical folate deficiency. * **Sulfasalazine:** Used in inflammatory bowel disease, it acts as a competitive inhibitor of the reduced folate carrier (RFC), significantly impairing the intestinal absorption of dietary folate. **NEET-PG High-Yield Pearls:** 1. **DHFR Inhibitors:** Drugs like **Methotrexate, Pyrimethamine, and Trimethoprim** are classic causes of megaloblastic anemia as they inhibit Dihydrofolate Reductase. 2. **DNA Synthesis Inhibitors:** **5-Fluorouracil, Hydroxyurea, and Zidovudine (AZT)** can cause megaloblastic changes without necessarily lowering folate levels. 3. **Oral Contraceptives:** Can occasionally interfere with folate absorption. 4. **Management:** When treating megaloblastic anemia caused by DHFR inhibitors, **Folinic acid (Leucovorin)** is preferred over Folic acid to bypass the inhibited enzyme.
Question 110: All of the following drugs can cause cholestatic jaundice except:
- A. Ethambutol (Correct Answer)
- B. Chlorpromazine
- C. Erythromycin estolate
- D. Estrogens
Explanation: **Explanation:** The correct answer is **Ethambutol**. This question tests your ability to differentiate between types of drug-induced liver injury (DILI), specifically identifying which drugs cause **cholestatic** versus **hepatocellular** damage. **1. Why Ethambutol is the correct answer:** Ethambutol is primarily known for its **ocular toxicity** (optic neuritis). Unlike other first-line anti-tubercular drugs like Isoniazid, Rifampicin, and Pyrazinamide, Ethambutol is generally **not hepatotoxic**. It does not typically cause cholestasis or significant elevations in liver enzymes, making it the "safe" anti-TB drug in patients with pre-existing liver disease. **2. Why the other options are incorrect:** * **Chlorpromazine:** This is the classic prototype for **drug-induced cholestasis**. It causes a hypersensitivity-type reaction leading to "bland cholestasis" or inflammatory cholestatic jaundice. * **Erythromycin estolate:** This specific salt of erythromycin is notorious for causing **cholestatic hepatitis**, likely due to a hypersensitivity reaction. It is the most common cause of drug-induced jaundice in adults taking macrolides. * **Estrogens:** Found in oral contraceptives, estrogens interfere with the bile salt transport system (canalicular secretion), leading to **dose-dependent cholestasis**. **Clinical Pearls for NEET-PG:** * **Hepatocellular Damage (High ALT/AST):** Isoniazid, Pyrazinamide, Paracetamol, Halothane. * **Cholestatic Jaundice (High ALP/Bilirubin):** Chlorpromazine, Erythromycin estolate, Anabolic steroids, Oral Contraceptives, Methyltestosterone. * **Ethambutol Mnemonic:** Remember **"E"** for **E**ye (Optic neuritis) and **E**xcretion (Renal). It spares the liver! * **Optic Neuritis:** Patients on Ethambutol must be monitored for red-green color blindness and visual acuity changes.
Practice by Chapter
Principles of Clinical Pharmacology
Practice Questions
Therapeutic Drug Monitoring
Practice Questions
Drug Toxicity and Overdose
Practice Questions
Antidotes and Their Applications
Practice Questions
Management of Drug Poisoning
Practice Questions
Drug-Induced Liver Injury
Practice Questions
Drug-Induced Kidney Injury
Practice Questions
Drug-Induced Blood Dyscrasias
Practice Questions
Drug-Induced QT Prolongation
Practice Questions
Pharmacovigilance
Practice Questions
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free